We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Boehringer Ingelheim forms partnerships

Boehringer Ingelheim forms partnerships

March 16, 2011
CenterWatch Staff

Boehringer Ingelheim has entered into an antibody deal with fellow German firm MorphoSys and signed a diabetes technology pact with Depomed, according to Pharma Times.

The MorphoSys agreement covers the process development and manufacturing of additional clinical material for MOR208, a monoclonal anti-CD19 antibody for the treatment of chronic lymphocytic leukaemia and potentially other B-cell malignancies. It is currently being evaluated in a phase I trial in the U.S. by MorphoSys's partner Xencor.

Simon Sturge, head of the biopharmaceuticals division at Boehringer, said the combination of MorphoSys' track record in the discovery and clinical side of antibody-based therapeutics "and our proven competence in technical development and manufacturing will be an optimal fit."

Boehringer has obtained worldwide rights to Depomed's Acuform gastric retentive drug delivery technology to develop certain fixed-dose combination products which include extended-release metformin and Boehringer compounds for type II diabetes.

Boehringer is paying a $12.5 million license fee, $10 million upfront and an additional $2.5 million payable upon delivery of experimental batches of prototype formulations. Depomed is also eligible to receive additional milestone payments and royalties.

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing